Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod tablet versus capsule relative bioavailability and pharmacokinetics study in healthy volunteers
NL-OMON43112Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of laquinimod in multiple sclerosis (MS) and Huntington disease (HD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Relative bioavailability of laquinimod tablet versus capsule. Started Oct 2016; status: active, not recruiting.
02
Drugs
laquinimod
03
Conditions
multiple sclerosis (MS)Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON43112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43112.